| 4.75 0.099 (2.12%) | 02-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.27 |
1-year : | 7.32 |
| Resists | First : | 5.36 |
Second : | 6.27 |
| Pivot price | 0.91 |
|||
| Supports | First : | 2.39 |
Second : | 0.55 |
| MAs | MA(5) : | 1.43 |
MA(20) : | 0.86 |
| MA(100) : | 0.68 |
MA(250) : | 0.56 |
|
| MACD | MACD : | 0.3 |
Signal : | 0 |
| %K %D | K(14,3) : | 36.4 |
D(3) : | 27.4  |
| RSI | RSI(14): 95.8 |
|||
| 52-week | High : | 5.36 | Low : | 0.21 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RLYB ] has closed above the upper band by 43.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 2396.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.37 - 5.4 | 5.4 - 5.42 |
| Low: | 4.36 - 4.38 | 4.38 - 4.4 |
| Close: | 4.71 - 4.74 | 4.74 - 4.78 |
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Wed, 04 Feb 2026
Rallybio To Implement 1 For 8 Reverse Stock Split To Regain Nasdaq Compliance;Stock Down - Nasdaq
Tue, 03 Feb 2026
Rallybio announces reverse 1-for-8 stock split - TipRanks
Tue, 03 Feb 2026
Rallybio announces one-for-eight reverse stock split effective Feb 6 - Investing.com
Tue, 03 Feb 2026
Rallybio reverse split swaps 8 shares for 1, cash for fractions - stocktitan.net
Thu, 29 Jan 2026
Rallybio Shareholders Approve Reverse Stock Split Amendment - TipRanks
Thu, 07 Aug 2025
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 2.032e+007 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 123 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.314e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 266.5 % |
| Return on Equity (ttm) | -28.4 % |
| Qtrly Rev. Growth | 674000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -35 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.33 |
| Dividend | 0 |
| Forward Dividend | 116610 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|